{"id":"gsk-biologicals-meningococcal-vaccine-gsk134612","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or erythema"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL2109142","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains antigens from meningococcal serogroups designed to elicit both humoral and cellular immune responses. By priming the adaptive immune system against these bacterial pathogens, the vaccine provides protection against invasive meningococcal disease and meningitis caused by the targeted serogroups.","oneSentence":"GSK134612 is a meningococcal vaccine that stimulates the immune system to produce antibodies against multiple serogroups of Neisseria meningitidis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:14:38.070Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of invasive meningococcal disease"}]},"trialDetails":[{"nctId":"NCT01939158","phase":"PHASE3","title":"Immunogenicity and Safety Study of 1 and 2 Doses of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine MenACWY-TT (GSK134612) in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer's Prevenar 13™Vaccine","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-10-02","conditions":"Infections, Meningococcal","enrollment":803},{"nctId":"NCT00955682","phase":"PHASE3","title":"Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK134612","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-08-25","conditions":"Infections, Meningococcal","enrollment":342},{"nctId":"NCT01144663","phase":"PHASE3","title":"Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07-01","conditions":"Infections, Meningococcal, Meningococcal Vaccines","enrollment":2095},{"nctId":"NCT01266993","phase":"PHASE3","title":"Persistence and Booster Study of GSK Biologicals' Meningococcal Vaccine (GSK134612) in Healthy Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-01-03","conditions":"Infections, Meningococcal, Meningococcal Vaccines","enrollment":271},{"nctId":"NCT00514904","phase":"PHASE3","title":"Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 2-10 Year Old Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-09-18","conditions":"Infections, Meningococcal, Meningococcal Vaccines","enrollment":1504},{"nctId":"NCT00474266","phase":"PHASE3","title":"Safety & Immunogenicity Study of Meningococcal Vaccine GSK134612 Given With Priorix-Tetra™ to 12-23 Month-Old Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-06-05","conditions":"Infections, Meningococcal","enrollment":1000},{"nctId":"NCT00674583","phase":"PHASE3","title":"Comparison of GSK Biologicals' Meningococcal Vaccine (GSK134612) and Licensed MenC-CRM197 Vaccine in Healthy Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-05-09","conditions":"Infections, Meningococcal","enrollment":414},{"nctId":"NCT01934140","phase":"PHASE3","title":"Study to Evaluate the Long-term Antibody Persistence of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine (GSK134612) Versus Mencevax ACWY in Healthy Adolescents and Adults and Booster Response to MenACWY-TT Vaccine Administered at 10 Years Post-primary Vaccination","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-04","conditions":"Infections, Meningococcal","enrollment":311},{"nctId":"NCT01340898","phase":"PHASE3","title":"Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Conjugate Vaccine When Co-administered With Routine Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-01-27","conditions":"Meningococcal Infection","enrollment":753},{"nctId":"NCT00718666","phase":"PHASE2","title":"The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Toddlers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-10-20","conditions":"Infections, Meningococcal","enrollment":387},{"nctId":"NCT00471081","phase":"PHASE2","title":"Immunogenicity and Safety of Meningococcal Vaccine GSK134612 Given as 1 or 2 Doses to Healthy 9-12 Months Old Toddlers.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-07-05","conditions":"Infections, Meningococcal","enrollment":385},{"nctId":"NCT01777308","phase":"PHASE3","title":"Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary Vaccination","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-05-03","conditions":"Infections, Meningococcal","enrollment":156},{"nctId":"NCT00508261","phase":"PHASE3","title":"Co-Administration of Meningococcal Vaccine GSK134612 With Infanrix Hexa™ Versus Individual Administration of Each Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-08-01","conditions":"Infections, Meningococcal","enrollment":793},{"nctId":"NCT00661557","phase":"PHASE2","title":"Comparison of GSK134612 in Subjects Previously Vaccinated Against Meningococcal Disease Versus Non-vaccinated Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-05-19","conditions":"Infections, Meningococcal","enrollment":271},{"nctId":"NCT01154088","phase":"PHASE3","title":"Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Versus Mencevax™ ACWY in Healthy 18-25 Year Olds","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-08-27","conditions":"Infections, Meningococcal","enrollment":1170},{"nctId":"NCT00453986","phase":"PHASE3","title":"Lot Consistency, Immuno, Safety of Meningococcal Vaccine GSK134612 Given With Fluarix™ to 18-55 Year-Old Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-04-09","conditions":"Infections, Meningococcal","enrollment":1352},{"nctId":"NCT00614614","phase":"PHASE3","title":"Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-02-13","conditions":"Infections, Meningococcal","enrollment":1558},{"nctId":"NCT01235975","phase":"PHASE3","title":"Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine Given as One Dose to Healthy Subjects Above 56 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-11-30","conditions":"Infections, Meningococcal","enrollment":400},{"nctId":"NCT01755689","phase":"PHASE3","title":"Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-01-11","conditions":"Infections, Meningococcal","enrollment":1300},{"nctId":"NCT01165242","phase":"PHASE2","title":"Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-08-19","conditions":"Infections, Meningococcal","enrollment":1013},{"nctId":"NCT00464815","phase":"PHASE3","title":"Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 11-17 Year-Old Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-05-02","conditions":"Infections, Meningococcal","enrollment":1025},{"nctId":"NCT00454909","phase":"PHASE2","title":"Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-04-23","conditions":"Infections, Meningococcal","enrollment":873},{"nctId":"NCT00196976","phase":"PHASE2","title":"Safety & Immunogenicity of 1 Dose of GSK134612 in Children 12-14 Months and 3-5 Years Old","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-03-24","conditions":"Infections, Meningococcal","enrollment":461},{"nctId":"NCT00758264","phase":"PHASE3","title":"Co-administration of Meningococcal Vaccine GSK134612 and Pneumococcal Vaccine GSK1024850A vs Individual Administration","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-10-30","conditions":"Infections, Meningococcal","enrollment":363},{"nctId":"NCT01641042","phase":"PHASE3","title":"Comparison of GlaxoSmithKline (GSK)134612 in Subjects With Increased Risk for Meningococcal Disease Versus Healthy Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-09-10","conditions":"Infections, Meningococcal","enrollment":86},{"nctId":"NCT01767376","phase":"PHASE3","title":"Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Conjugate Vaccine (GSK134612) When Co-administered With Boostrix® in Subjects Between 11 and 25 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-01-10","conditions":"Infections, Meningococcal","enrollment":692},{"nctId":"NCT00974363","phase":"PHASE3","title":"Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK 134612","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-09","conditions":"Infections, Meningococcal","enrollment":697},{"nctId":"NCT00715910","phase":"PHASE2","title":"The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Adolescents/Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-07","conditions":"Infections, Meningococcal","enrollment":818}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"GSK Biologicals' meningococcal vaccine GSK134612","genericName":"GSK Biologicals' meningococcal vaccine GSK134612","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"GSK134612 is a meningococcal vaccine that stimulates the immune system to produce antibodies against multiple serogroups of Neisseria meningitidis. Used for Prevention of invasive meningococcal disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}